Acrux - Drug delivery technology
Acrux’s innovative transdermal technology has led to the development and commercialisation of multiple pharmaceuticals, namely AXIRON, a spray-on testosterone solution. This product provides a less invasive treatment with fewer fluctuations for people with testosterone deficiency, providing potentially thousands of users with the benefits of stable testosterone levels including improved bone density, mood and cognition.
Year established: 1998
MD & CEO: Michael Kotsanis
Website: acrux.com.au